

Schwartz
EXHIBIT NO 51
Ave 1/4/08

Unknown

From: Schwartz, Jack A
Sent: Sunday, October 24, 2004 3:45 PM
To: Hoegstedt, Johan
Subject: RE: Clinical Studies Opportunities

Hi Johan,

Certainly. I didn't want Sarah to get the impression and start talking with NMA members that we are examining diabetes in a study. I fully support and will progress discussion with Sarah and subsequently medical leaders in NMA.

Thanks,

Jack

-----Original Message-----

From: Hoegstedt, Johan
Sent: Friday, October 22, 2004 3:26 PM
To: Schwartz, Jack A
Subject: RE: Clinical Studies Opportunities

Jack - is not the key area to consider glucose metabolism as a predictor? If we want to add an arm doing it through NMA provides significant leverage and building some of these alliances and that is the reason David put Sarah on loan. It may be worth at least initiating some discussions with their medical leaders.

Johan

-----Original Message-----

From: Schwartz, Jack A
Sent: Friday, October 22, 2004 8:12 AM
To: Hoegstedt, Johan; Harrison, Sarah S; Hickey, Michael P (US Sales)
Cc: Beamish, Don G
Subject: RE: Clinical Studies Opportunities

Sarah,

Please hold off contacting NMA leaders for the moment. Trial 125 is not a diabetes trial. We are examining glucose metabolism in this study. I have asked the study team to consider adding US sites to this study and am waiting for a response. I will come back to you with more details.

Thanks,

Jack

-----Original Message-----

From: Hoegstedt, Johan
Sent: Friday, October 22, 2004 8:06 AM
To: Harrison, Sarah S; Hickey, Michael P (US Sales)
Cc: Schwartz, Jack A; Beamish, Don G
Subject: RE: Clinical Studies Opportunities

Sarah,

At this point we do not have any specifics. Michael and I spoke about possible areas of interest and one area that has come up from some of the urban KOLs is the issues with weight gain and probably more importantly the metabolic impact of Zyprexa and possibly Risperdal on the African American and Hispanic populations. Right now we don't have any funds budgeted for such a trial and no protocol... However, there is a European trial ongoing and it may be worth having some of the NMA leaders within Psychiatry initiate a conversation directly with Jack Schwartz to see if there are any mutual interests. At this time I would not want to promise

a study but at least see what some possibilities could look like, even if it is something smaller like adding an additional arm to the current European study or to have them propose an ISS within their own areas of interest to Jack.

Thanks for all your help,

Johan

Jack and Don, as you may know Sarah is currently working within NMA on AZ's behalf

-----Original Message-----

From: Harrison, Sarah S
Sent: Wednesday, October 20, 2004 5:38 PM
To: Hickey, Michael P (US Sales)
Cc: Hoegstedt, Johan
Subject: RE: Clinical Studies Opportunities

Please provide me with the study objectives and a copy of a protocol if one exist. If not please share your interest in studying seroquel in diabetic patients. Also will this be for an expanded label claim? I will facilitate a discussion as soon as I receive a bit more information from you guys or from your clinical support people.

As you probably know a substantial % of SSRI's are used by minority patients, therefore you shouldn't have problems getting patients. I would also like to know the breakdown of your patient/user base by race, gender and age.

Thanks and I hope I can help.

sarah harrison

-----Original Message-----

From: Hickey, Michael P (US Sales)
Sent: Wednesday, October 20, 2004 2:14 PM
To: Harrison, Sarah S
Cc: Hoegstedt, Johan
Subject: Clinical Studies Opportunities

Both Johan and I are very keen to carry out clinical studies in diverse populations. In particular, we would be interested in a study on SEROQUEL in diabetes in both African American and Hispanic communities.

I would very much appreciate if you would take some steps here to guide us in how best to implement this using your contacts at the NMA.

mh